Skip to main content

Prelude Therapeutics Inc

PRLD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001678660

No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Prelude Therapeutics Inc changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of PRLD: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders5761+4
Shares34.5M36.0M+1.51M (+4.4%)
Value$986.6M$1.12B+$137.3M (+13.9%)

New holders (9)

Institutions that held Prelude Therapeutics Inc at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to PRLD in Q3 2021
InstitutionSharesValue% of portfolio
HRT Financial LP15,559$486.0K0.00%
Citadel Advisors LLC14,495$453.0K0.00%
Parametric Portfolio Associates LLC10,130$317.0K0.00%
SG Americas Securities, LLC8,691$272.0K0.00%
Virtu Financial LLC7,940$248.0K0.02%
Credit Suisse AG6,950$216.0K0.00%
Point72 Hong Kong Ltd1,602$50.0K0.00%
Quantbot Technologies LP200$6.00K0.00%
US Bancorp158$5.00K0.00%

Sold out (5)

Institutions that held Prelude Therapeutics Inc at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of PRLD in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Voloridge Investment Management, LLC15,319$439.0K
Jump Financial, LLC13,700$392.0K
Two Sigma Investments, LP10,116$290.0K
ARS Investment Partners, LLC7,400$212.0K
Dark Forest Capital Management LP155$4.00K